Tuesday, November 22, 2016

BRIEF-GSK's Mepolizumab meets endpoints in phase 3 EGPA study

* Phase lll study of mepolizumab meets co-primary endpoints

and all secondary endpoints in patients with eosinophilic

granulomatosis with polyangiitis

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)